Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Biochemical target isolation for novices: affinity-based strategies.

Sato S, Murata A, Shirakawa T, Uesugi M.

Chem Biol. 2010 Jun 25;17(6):616-23. doi: 10.1016/j.chembiol.2010.05.015. Review.

2.

Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action.

Hillenmeyer ME, Ericson E, Davis RW, Nislow C, Koller D, Giaever G.

Genome Biol. 2010;11(3):R30. doi: 10.1186/gb-2010-11-3-r30. Epub 2010 Mar 12.

3.

Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death.

Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA.

Mol Cancer Ther. 2009 Aug;8(8):2183-92. doi: 10.1158/1535-7163.MCT-08-1203. Epub 2009 Aug 11.

4.

The combined status of ATM and p53 link tumor development with therapeutic response.

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT.

Genes Dev. 2009 Aug 15;23(16):1895-909. doi: 10.1101/gad.1815309. Epub 2009 Jul 16.

5.

TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II.

Akhtar MS, Heidemann M, Tietjen JR, Zhang DW, Chapman RD, Eick D, Ansari AZ.

Mol Cell. 2009 May 15;34(3):387-93. doi: 10.1016/j.molcel.2009.04.016.

6.

Targeting p53 for enhanced radio- and chemo-sensitivity.

Lu C, El-Deiry WS.

Apoptosis. 2009 Apr;14(4):597-606. doi: 10.1007/s10495-009-0330-1. Review.

PMID:
19259822
7.

Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer.

Lavin MF.

Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69. doi: 10.1038/nrm2514. Review. Erratum in: Nat Rev Mol Cell Biol. 2008 Dec;9(12). doi: 10.1038/nrm2514.

PMID:
18813293
8.

ATR: an essential regulator of genome integrity.

Cimprich KA, Cortez D.

Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27. doi: 10.1038/nrm2450. Epub 2008 Jul 2. Review.

9.

Topoisomerase levels determine chemotherapy response in vitro and in vivo.

Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT.

Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9053-8. doi: 10.1073/pnas.0803513105. Epub 2008 Jun 23.

10.

The chemical genomic portrait of yeast: uncovering a phenotype for all genes.

Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, Lee W, Proctor M, St Onge RP, Tyers M, Koller D, Altman RB, Davis RW, Nislow C, Giaever G.

Science. 2008 Apr 18;320(5874):362-5. doi: 10.1126/science.1150021.

11.

The BCL-2 protein family: opposing activities that mediate cell death.

Youle RJ, Strasser A.

Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59. Review.

PMID:
18097445
13.

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6. Epub 2007 Apr 30.

14.
15.

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR.

Cancer Cell. 2006 Oct;10(4):321-30. Epub 2006 Sep 28.

16.

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR.

Science. 2006 Sep 29;313(5795):1929-35.

17.

The NCI60 human tumour cell line anticancer drug screen.

Shoemaker RH.

Nat Rev Cancer. 2006 Oct;6(10):813-23. Review.

PMID:
16990858
18.

Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, Porter J, Chua G, Sopko R, Brost RL, Ho CH, Wang J, Ketela T, Brenner C, Brill JA, Fernandez GE, Lorenz TC, Payne GS, Ishihara S, Ohya Y, Andrews B, Hughes TR, Frey BJ, Graham TR, Andersen RJ, Boone C.

Cell. 2006 Aug 11;126(3):611-25.

19.

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

Williams RT, Roussel MF, Sherr CJ.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93. Epub 2006 Apr 17.

20.

Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW.

Nat Genet. 2005 Nov;37(11):1289-95. Epub 2005 Oct 2. Erratum in: Nat Genet. 2006 Mar;38(3):389.

PMID:
16200064

Supplemental Content

Support Center